secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001104659-23-029006
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cara Therapeutics Q4 2022 revenue $3.3M, net loss $30.3M; FY22 revenue $41.9M
-----------------------------------------------------------------------------

- Q4 2022 total revenue $3.3M (incl. $1.1M collaborative revenue from KORSUVA profit share); FY22 total revenue $41.9M.
- Q4 2022 net loss $30.3M ($0.56 per share); FY22 net loss $85.5M ($1.59 per share).
- Cash and equivalents $156.7M at Dec 31, 2022; expects to fund operations into first half of 2024.
- KORSUVA injection net sales $2.3M in Q4, $35.3M for FY22; wholesaler shipments 20,844 vials in Q4, 207,096 for FY22.
- Phase 2/3 program of oral difelikefalin for NP initiated; PMDA decision in Japan expected H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465923029006/0001104659-23-029006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465923029006/tm238541d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-029006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer